{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:35:49Z","timestamp":1761676549016},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"CAMS Initiative for Innovative Medicine (CAMS-I2M)","award":["2016-I2M-2-006"],"award-info":[{"award-number":["2016-I2M-2-006"]}]},{"name":"CAMS Initiative for Innovative Medicine (CAMS-I2M)","award":["2016-I2M-4-001"],"award-info":[{"award-number":["2016-I2M-4-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40360-017-0143-8","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T08:28:57Z","timestamp":1497860937000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and \u03b2-cell function in spontaneous diabetic KKAy mice"],"prefix":"10.1186","volume":"18","author":[{"given":"Caina","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaocong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuainan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Huan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhufang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,19]]},"reference":[{"key":"143_CR1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/00325481.2016.1103640","volume":"128","author":"CF Shaefer","year":"2016","unstructured":"Shaefer CF, Anderson J. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin. Postgrad Med. 2016;128:137\u201344.","journal-title":"Postgrad Med"},{"key":"143_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MED.0000000000000217","volume":"23","author":"B Gallwitz","year":"2016","unstructured":"Gallwitz B. Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances. Curr Opin Endocrinol Diabetes Obes. 2016;23:23\u20137.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"143_CR3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.tem.2016.03.004","volume":"27","author":"E Tudur\u00ed","year":"2016","unstructured":"Tudur\u00ed E, L\u00f3pez M, Di\u00e9guez C, Nadal A, Nogueiras R. Glucagon-like peptide 1 analogs and their effects on pancreatic islets. Trends Endocrinol Metab. 2016;27:304\u201318.","journal-title":"Trends Endocrinol Metab"},{"key":"143_CR4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s00125-011-2069-9","volume":"54","author":"M Shimoda","year":"2011","unstructured":"Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M, Kaku K. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011;54:1098\u2013108.","journal-title":"Diabetologia"},{"key":"143_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13300-012-0003-x","volume":"3","author":"ZZ Htike","year":"2012","unstructured":"Htike ZZ, Khunti K, Davies M. A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. Diabetes Ther. 2012;3:1\u201316.","journal-title":"Diabetes Ther"},{"key":"143_CR6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bbrc.2014.02.045","volume":"445","author":"L Zhang","year":"2014","unstructured":"Zhang L, Wang L, Meng Z, Gan H, Gu R, Wu Z, et al. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys. Biochem Biophys Res Commun. 2014;445:511\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"Spec Feature","key":"143_CR7","first-page":"126","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L. Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits. 2015;8(Spec Feature):126\u201330.","journal-title":"Am Health Drug Benefits"},{"key":"143_CR8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1586\/17512433.2016.1141046","volume":"9","author":"AJ Scheen","year":"2016","unstructured":"Scheen AJ. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol. 2016;9:385\u201399.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"143_CR9","first-page":"817839","volume":"2015","author":"S Hou","year":"2015","unstructured":"Hou S, Li C, Huan Y, Liu S, Liu Q, Sun S, et al. Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db\/db Mice. J Diabetes Res. 2015;2015:817839.","journal-title":"J Diabetes Res"},{"key":"143_CR10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejphar.2009.11.021","volume":"628","author":"G Song","year":"2010","unstructured":"Song G, Huan Y, Sun S, Chen Y, Liu Q, Shen Z. Biological activity of Exf, a peptide analogue of exendin-4. Eur J Pharmacol. 2010;628:261\u20137.","journal-title":"Eur J Pharmacol"},{"key":"143_CR11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1476-511X-13-98","volume":"13","author":"Z Chen","year":"2014","unstructured":"Chen Z, Liu S, Li C, Sun S, Liu Q, Lei L, et al. Atorvastatin helps preserve pancreatic \u03b2 cell function in obese C57BL\/6\u00a0J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress. Lipids Health Dis. 2014;13:98.","journal-title":"Lipids Health Dis"},{"key":"143_CR12","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jdiacomp.2016.05.018","volume":"30","author":"D Yabe","year":"2016","unstructured":"Yabe D, Ambos A, Cariou B, Duvnjak L, Evans M, Gonz\u00e1lez-G\u00e1lvez G, et al. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse \u03b2-cell function in the GetGoal-M and GetGoal-S trials. J Diabetes Complications. 2016;30:1385\u201392.","journal-title":"J Diabetes Complications"},{"key":"143_CR13","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.4158\/EP161337.OR","volume":"22","author":"JA Davidson","year":"2016","unstructured":"Davidson JA, Manghi FP, Yu M, Linetzky B, Land\u00f3 LF. Efficacy and Safety of Dulaglutide in Hispanic\/Latino Patients with Type 2 Diabetes in the AWARD Clinical Program. Endocr Pract. 2016;22:1406\u201314.","journal-title":"Endocr Pract"},{"key":"143_CR14","volume":"11","author":"Z Li","year":"2016","unstructured":"Li Z, Zhang Y, Quan X, Yang Z, Zeng X, Ji L, et al. Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLoS One. 2016;11, e0154206.","journal-title":"PLoS One"},{"key":"143_CR15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1530\/EJE-16-0286","volume":"175","author":"DH Raalte van","year":"2016","unstructured":"van Raalte DH, Bunck MC, Smits MM, Hoekstra T, Corn\u00e9r A, Diamant M, et al. Exenatide improves \u03b2-cell function up to 3\u00a0years of treatment in patients with type 2 diabetes: a randomised controlled trial. Eur J Endocrinol. 2016;175:345\u201352.","journal-title":"Eur J Endocrinol"},{"key":"143_CR16","doi-asserted-by":"crossref","first-page":"23403","DOI":"10.1038\/srep23403","volume":"6","author":"TJ Chang","year":"2016","unstructured":"Chang TJ, Tseng HC, Liu MW, Chang YC, Hsieh ML, Chuang LM. Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation. Sci Rep. 2016;6:23403.","journal-title":"Sci Rep"},{"key":"143_CR17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/MOL.0000000000000232","volume":"26","author":"W Rankin","year":"2015","unstructured":"Rankin W, Wittert G. Anti-obesity drugs. Curr Opin Lipidol. 2015;26:536\u201343.","journal-title":"Curr Opin Lipidol"},{"key":"143_CR18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13300-015-0127-x","volume":"6","author":"A Uccellatore","year":"2015","unstructured":"Uccellatore A, Genovese S, Dicembrini I, Mannucci E, Ceriello A. Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists. Diabetes Ther. 2015;6:239\u201356.","journal-title":"Diabetes Ther"},{"key":"143_CR19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40261-016-0376-0","volume":"36","author":"T Vilsb\u00f8ll","year":"2016","unstructured":"Vilsb\u00f8ll T, Vora J, Jarlov H, Kvist K, Blonde L. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clin Drug Investig. 2016;36:293\u2013303.","journal-title":"Clin Drug Investig"},{"key":"143_CR20","first-page":"245","volume":"23","author":"A Chatzigeorgiou","year":"2009","unstructured":"Chatzigeorgiou A, Halapas A, Kalafatakis K, Kamper E. The use of animal models in the study of diabetes mellitus. In Vivo. 2009;23:245\u201358.","journal-title":"In Vivo"},{"key":"143_CR21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","volume":"26","author":"L Monnier","year":"2003","unstructured":"Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881\u20135.","journal-title":"Diabetes Care"},{"key":"143_CR22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00325481.2016.1174565","volume":"128","author":"JE Matthews","year":"2016","unstructured":"Matthews JE, Reinhardt RR, Carr MC. Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes. Postgrad Med. 2016;128:391\u20137.","journal-title":"Postgrad Med"},{"key":"143_CR23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0033-1358527","volume":"33","author":"JE Mells","year":"2013","unstructured":"Mells JE, Anania FA. The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis. 2013;33:343\u201357.","journal-title":"Semin Liver Dis"},{"key":"143_CR24","doi-asserted-by":"crossref","first-page":"e49152","DOI":"10.1371\/journal.pone.0049152","volume":"7","author":"ET Parlevliet","year":"2012","unstructured":"Parlevliet ET, Wang Y, Geerling JJ, der Elst JP S\u00d6-V, Picha K, O\u2019Neil K, et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One. 2012;7:e49152.","journal-title":"PLoS One"},{"key":"143_CR25","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2337\/db07-1775","volume":"57","author":"KM Picha","year":"2008","unstructured":"Picha KM, Cunningham MR, Drucker DJ, Mathur A, Ort T, Scully M, et al. Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes. 2008;57:1926\u201334.","journal-title":"Diabetes"},{"key":"143_CR26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1053\/j.gastro.2008.01.017","volume":"134","author":"LL Baggio","year":"2008","unstructured":"Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology. 2008;134:1137\u201347.","journal-title":"Gastroenterology"},{"key":"143_CR27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","volume":"26","author":"W Glaesner","year":"2010","unstructured":"Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287\u201396.","journal-title":"Diabetes Metab Res Rev"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-017-0143-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T08:29:09Z","timestamp":1497860949000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-017-0143-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,19]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["143"],"URL":"https:\/\/doi.org\/10.1186\/s40360-017-0143-8","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,19]]},"article-number":"48"}}